Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biotechnology company specializing in treating liver disease and obesity.

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

Colonic air insufflation averaged 30 bulb compressions. Thirty-three patients received IV glucagon (1 mg), and 27 patients did not. The colon was divided into eight segments, and the adequacy of ...

Ozempic belongs to a group of drugs called glucagon-like peptide-1 receptor ... any time of day 4 mg/3 mL, used for maintenance dosages 1 mg, given after 4 weeks of the 0.5-mg dose if blood ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

Glucagon-like peptide-1 (GLP-1) receptor agonists ... “CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo ...